Imeglimin: Difference between revisions
Appearance
Content deleted Content added
ref |
mNo edit summary Tags: Visual edit Mobile edit Mobile web edit |
||
(16 intermediate revisions by 13 users not shown) | |||
Line 1: | Line 1: | ||
{{short description|Chemical compound}} |
|||
{{Chembox |
|||
{{Infobox drug |
|||
⚫ | |||
| drug_name = |
|||
| ImageSize = 150px |
|||
| INN = |
|||
⚫ | |||
| type = <!-- empty --> |
|||
| OtherNames = |
|||
⚫ | |||
|Section1={{Chembox Identifiers |
|||
| width = 150px |
|||
⚫ | |||
| |
| alt = |
||
| caption = |
|||
⚫ | |||
<!-- Clinical data --> |
|||
⚫ | |||
| pronounce = |
|||
⚫ | |||
| tradename = Twymeeg |
|||
⚫ | |||
| Drugs.com = |
|||
| StdInChI = 1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1 |
|||
| MedlinePlus = |
|||
| StdInChIKey = GFICWFZTBXUVIG-SCSAIBSYSA-N |
|||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|||
}} |
|||
| pregnancy_AU_comment = |
|||
|Section2={{Chembox Properties |
|||
| pregnancy_category= |
|||
| routes_of_administration = |
|||
| ATCvet = |
|||
| ATC_prefix = A10 |
|||
| ATC_suffix = BX15 |
|||
<!-- Legal status --> |
|||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
|||
| legal_AU_comment = |
|||
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F --> |
|||
| legal_BR_comment = |
|||
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|||
| legal_CA_comment = |
|||
| legal_DE = <!-- Anlage I, II, III or Unscheduled --> |
|||
| legal_DE_comment = |
|||
| legal_NZ = <!-- Class A, B, C --> |
|||
| legal_NZ_comment = |
|||
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> |
|||
| legal_UK_comment = |
|||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|||
| legal_US_comment = |
|||
| legal_EU = |
|||
| legal_EU_comment = |
|||
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> |
|||
| legal_UN_comment = |
|||
| legal_status = Rx-only in Japan |
|||
<!-- Pharmacokinetic data --> |
|||
| bioavailability = |
|||
| protein_bound = |
|||
| metabolism = |
|||
| metabolites = |
|||
| onset = |
|||
| elimination_half-life = |
|||
| duration_of_action= |
|||
| excretion = |
|||
<!-- Identifiers --> |
|||
⚫ | |||
| PubChem = 24812808 |
|||
| UNII = UU226QGU97 |
|||
⚫ | |||
| DrugBank = |
|||
<!-- Chemical and physical data --> |
|||
⚫ | |||
| C=6 | H=13 | N=5 |
| C=6 | H=13 | N=5 |
||
⚫ | |||
| Appearance = |
|||
⚫ | |||
| Density = |
|||
⚫ | |||
| MeltingPt = |
|||
| BoilingPt = |
|||
| Solubility = |
|||
}} |
|||
|Section3={{Chembox Hazards |
|||
| MainHazards = |
|||
| FlashPt = |
|||
| AutoignitionPt = |
|||
}} |
|||
}} |
}} |
||
'''Imeglimin''' (EMD- 387008,PXL- 008,RVT-1501, brand name '''Twymeeg''') is an oral [[anti-diabetic]] medication.<ref>{{cite journal | vauthors = Vuylsteke V, Chastain LM, Maggu GA, Brown C | title = Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes | journal = Drugs in R&D | volume = 15 | issue = 3 | pages = 227–32 | date = September 2015 | pmid = 26254210 | pmc = 4561051 | doi = 10.1007/s40268-015-0099-3 }}</ref><ref>{{cite journal | vauthors = Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K | title = Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial | journal = Diabetes Care | volume = 44 | issue = 4 | pages = 952–959 | date = April 2021 | pmid = 33574125 | doi = 10.2337/dc20-0763 | doi-access = free }}</ref> It was approved for use in Japan in June 2021.<ref>{{cite press release | title = Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan | url = https://www.businesswire.com/news/home/20210622006160/en/Poxel-and-Sumitomo-Dainippon-Pharma-Announce-the-Approval-of-TWYMEEG%C2%AE-Imeglimin-hydrochloride-for-the-Treatment-of-Type-2-Diabetes-in-Japan | author = Poxel SA | date = June 23, 2021 }}</ref> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
{{reflist}} |
{{reflist}} |
||
{{Oral_hypoglycemics}} |
|||
⚫ | |||
⚫ | |||
{{gastrointestinal-drug-stub}} |
{{gastrointestinal-drug-stub}} |
Latest revision as of 16:44, 26 September 2023
![]() | |
Clinical data | |
---|---|
Trade names | Twymeeg |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C6H13N5 |
Molar mass | 155.205 g·mol−1 |
3D model (JSmol) | |
| |
|
Imeglimin (EMD- 387008,PXL- 008,RVT-1501, brand name Twymeeg) is an oral anti-diabetic medication.[1][2] It was approved for use in Japan in June 2021.[3]
It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It is the first approved drug of this class of anti-diabetic medication.
References
[edit]- ^ Vuylsteke V, Chastain LM, Maggu GA, Brown C (September 2015). "Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes". Drugs in R&D. 15 (3): 227–32. doi:10.1007/s40268-015-0099-3. PMC 4561051. PMID 26254210.
- ^ Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K (April 2021). "Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial". Diabetes Care. 44 (4): 952–959. doi:10.2337/dc20-0763. PMID 33574125.
- ^ Poxel SA (June 23, 2021). "Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan" (Press release).